Predictors of variability in bosutinib distribution and elimination from the 
hepatic impairment, renal impairment, end‐stage renal disease, Cancer
HEPATIC IMPAIRMENT, RENAL IMPAIRMENT, DYSFUNCTION, CANCER
Bosutinib systemic clearance (CL) was estimated to be 56.3 L/h with 43.4% inter‐individual variance (IIV). Central volume of distribution (VDemographic factors and measures of renal and hepatic function were evaluated as possible covariates contributing to the variability in PK parameters of bosutinib (Table When assessing the effect of renal function upon the PK of bosutinib based on baseline creatinine clearance (BCCL), it was found that, relative to an individual with normal renal function (BCCL = 98.6 mL/min), bosutinib CL decreased by 5.3% for mild renal impairment (BCCL = 75 mL/min), 14.4% for moderate renal impairment (BCCL = 45 mL/min), 25.7% for severe renal impairment (BCCL = 22 mL/min), and 31.1% for end‐stage renal disease (BCCL = 15 mL/min). There were no discernible changes in bosutinib PK with baseline National Cancer Institute Organ Dysfunction Working Group (NCI ODWG) criteria for hepatic impairment or with any of the baseline laboratory values. Additionally, baseline AST and baseline total bilirubin were not significant covariates on bosutinib CL.